Navigation Links
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Date:8/19/2013

effective at 5:00 p.m. EDT on Tuesday, August 20, 2013.

Stockholders holding shares in "street name" through a brokerage account will have their shares automatically adjusted to reflect the reverse stock split and change in name.  

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.  The Company's product Ceplene®, when used concomitantly with low-dose IL-2 is intended as remission maintenance therapy in the treatment of AML for adult patients who are in their first complete remission.  The Company sold all of its rights to Ceplene® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene® inventory to Meda AB in June 2012.  The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.  In November 2012, EpiCept and Immune Pharmaceuticals Ltd., a privately held Israeli company, entered into a definitive merger agreement.  The transaction is anticipated to close this week.  The combined company will be focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.

About Immune Pharmaceuticals Ltd.

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics to address unmet medical needs in the treatment of inflammatory diseases and cancer. Im
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EpiCept Reports Second Quarter 2013 Operating and Financial Results
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced that it intends to file ... and Drug Administration,(FDA) for its innovative, anti-infective ... reviewing the data from our recently completed ...
... Life Science,Network has announced today that it will ... and measurable new life science business,for Michigan companies. ... the Michigan Virtual,Medical Device Company, LLC will launch ... the MichBio Expo annual convention in Lansing, Michigan.,MichBio ...
... Oct. 9 PARI Respiratory Equipment,s,breath-enhanced nebulizer, ... compressor,deliver Dey, L.P.,s new COPD medication, Perforomist ... is a subsidiary of Mylan Inc.,(NYSE: ... Solution is indicated for,long-term, twice-daily maintenance treatment ...
Cached Biology Technology:Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 2Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 3Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 4Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 5Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial 6Michigan Life Science Network to Form Two New Virtual Companies 2Michigan Life Science Network to Form Two New Virtual Companies 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 4
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
(Date:7/30/2014)... protected and tended her eggs until they hatched 4.5 ... 2014 in the open-access journal PLOS ONE ... and colleagues. , Octopuses typically have a single reproductive ... take care of their fertilized eggs until they hatch. ... to 3 months, but little is known about the ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... College Park, Md. (April 6, 2011) -- Most people experience X-ray ... tumor or blood clot. But in the lab of Dr. Quin ... a novel use of CT scanners as part of an agriculture ... a conveyor belt went little potted rice plants in an automated ...
... NY, April 6, 2011 The successful use ... and reduce the risk of neurological consequences following ... premier issue of Therapeutic Hypothermia and Temperature ... by Mary Ann Liebert, Inc. This groundbreaking new ...
... affects intake of caffeine, the most widely consumed stimulant in ... from the National Cancer Institute, Harvard School of Public Health, ... at Chapel Hill examined genetic variation across the entire genome ... in the open-access journal PLoS Genetics . ...
Cached Biology News:Seeing rice with X-rays may improve crop yields 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 2Hypothermia proven to improve survival and outcomes following out-of-hospital cardiac arrest 3
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
... kit is a sample preparation kit for ... removal of detergents, phenolic compounds, salts, and ... dilute samples. The kit procedure involves a ... tissue or cells, plant leaves, E. coli, ...
... is intended for first-time users of the PROTEAN ... includes a protein sample and reagents sufficient to ... 17 cm, ten 11 cm, or sixteen 7 ... precast SDS-PAGE gels and gels stains are not ...
... Immunogen : Fusion protein ... 474-970 of human Mi-2 Formulation: ... NaCl, 0.035% sodium azide, containing ... evaluated by immunoblot on Hela ...
Biology Products: